Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Will Novel Agents Impact The HIV Market?

Executive Summary

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 

You may also be interested in...



J&J’s Symtuza Approved, But Commercial Outlook Uncertain

The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.

Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo

The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.

First Efficacy Study for Janssen's Mosaic HIV-1 Preventive Vaccine Starting

Proof-of-concept trialing will soon begin for Janssen's promising HIV-1 prophylactic vaccine, with backing from the Gates Foundation and the NIH.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC122903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel